These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21468307)

  • 1. Vaccines for the leishmaniases: proposals for a research agenda.
    ; Costa CH; Peters NC; Maruyama SR; de Brito EC; Santos IK
    PLoS Negl Trop Dis; 2011 Mar; 5(3):e943. PubMed ID: 21468307
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccines for leishmaniasis: from proteome to vaccine candidates.
    Schroeder J; Aebischer T
    Hum Vaccin; 2011; 7 Suppl():10-5. PubMed ID: 21245661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying vaccine targets for anti-leishmanial vaccine development.
    Sundar S; Singh B
    Expert Rev Vaccines; 2014 Apr; 13(4):489-505. PubMed ID: 24606556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.
    Duthie MS; Reed SG
    Clin Vaccine Immunol; 2017 Jul; 24(7):. PubMed ID: 28515135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
    Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C
    Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide Vaccines for Leishmaniasis.
    De Brito RCF; Cardoso JMO; Reis LES; Vieira JF; Mathias FAS; Roatt BM; Aguiar-Soares RDDO; Ruiz JC; Resende DM; Reis AB
    Front Immunol; 2018; 9():1043. PubMed ID: 29868006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
    Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum.
    Vilela Mde C; Gomes DC; Marques-da-Silva Ede A; Serafim TD; Afonso LC; Rezende SA
    Acta Trop; 2007; 104(2-3):133-9. PubMed ID: 17919443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chitosan Nanoparticles Loaded with Whole and Soluble Leishmania Antigens, and Evaluation of Their Immunogenecity in a Mouse Model of Leishmaniasis.
    Hojatizade M; Soleymani M; Tafaghodi M; Badiee A; Chavoshian O; Jaafari MR
    Iran J Immunol; 2018 Dec; 15(4):281-293. PubMed ID: 30593742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmaniases control: what part for development and what part for research?
    Bastien P
    Clin Microbiol Infect; 2011 Oct; 17(10):1449-50. PubMed ID: 21933303
    [No Abstract]   [Full Text] [Related]  

  • 11. Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of Leishmania in the Indian Subcontinent.
    Olliaro PL; Shamsuzzaman TA; Marasini B; Dhariwal AC; Be-Nazir A; Mondal D; Banjara MR; Das P; Sundar S; Rijal S; Arana B; Alvar J; Argaw D; Peeling RW; Kroeger A; Matlashewski G
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005190. PubMed ID: 28125596
    [No Abstract]   [Full Text] [Related]  

  • 12. Leishmania vaccine development: A comprehensive review.
    Saini I; Joshi J; Kaur S
    Cell Immunol; 2024; 399-400():104826. PubMed ID: 38669897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of vaccinal effectiveness of preparations containing membrane antigens of Leishmania (L.) amazonensis in experimental cutaneous leishmaniasis model.
    Ribeiro JG; Ferreira AS; Macedo SRA; Rossi NRDLP; da Silva MCP; Guerra RNM; de Barros NB; Nicolete R
    Int Immunopharmacol; 2017 Jun; 47():227-230. PubMed ID: 28433944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meetings on vaccine studies towards the control of leishmaniasis. UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR) February 13-22 and April 4-5, 1995.
    Grimaldi Júnior G
    Mem Inst Oswaldo Cruz; 1995; 90(4):553-6. PubMed ID: 8551962
    [No Abstract]   [Full Text] [Related]  

  • 15. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.
    Heravi Shargh V; Jaafari MR; Khamesipour A; Jalali SA; Firouzmand H; Abbasi A; Badiee A
    Parasitol Res; 2012 Jul; 111(1):105-14. PubMed ID: 22223037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of two vaccine candidates against experimental leishmaniasis due to Leishmania major infection in four inbred mouse strains.
    Benhnini F; Chenik M; Laouini D; Louzir H; Cazenave PA; Dellagi K
    Clin Vaccine Immunol; 2009 Nov; 16(11):1529-37. PubMed ID: 19726616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-generation vaccines against leishmaniasis.
    Coler RN; Reed SG
    Trends Parasitol; 2005 May; 21(5):244-9. PubMed ID: 15837614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against
    Seyed N; Peters NC; Rafati S
    Front Immunol; 2018; 9():1227. PubMed ID: 29922288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant DNA-derived leishmania proteins: from the laboratory to the field.
    Kubar J; Fragaki K
    Lancet Infect Dis; 2005 Feb; 5(2):107-14. PubMed ID: 15680780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leishmaniasis vaccines: past, present and future.
    Modabber F
    Int J Antimicrob Agents; 2010 Nov; 36 Suppl 1():S58-61. PubMed ID: 20801000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.